Mabion Biologics is a Poland-based biologics company specializing in the development and GMP manufacturing of large-molecule therapeutics, including monoclonal antibodies, biosimilars, recombinant proteins, and emerging complex biologics (like bispecifics or ADCs). The company provides services covering cell line development, upstream and downstream bioprocessing, analytical development, quality control, logistics, clinical and commercial manufacturing. Mabion gained international recognition through its participation in recombinant spike antigen manufacturing activities related to the Novavax COVID-19 vaccine program. Mabion is a highly specialized European Drug Substance development and manufacturing partner focused on large molecule manufacturing, biosimilar programs, innovation-driven collaborations, and strategic co-development partnerships. The company aims to become the most flexible and technologically advanced large molecule partner for biologics in Europe, with strategic focus areas including ADCs, bispecific antibodies, highly potent biologics, biosimilars, and innovative CD20-based projects. Mabion S.A. is a public Company, listed on the Warsaw Stock Exchange (WSE: MAB). For more information about the Company, please visit www.mabion.eu
Looking for a particular Mabion S.A. employee's phone or email?
The Mabion S.A. annual revenue was $37.8 million in 2026.
Krzysztof Kaczmarczyk is the CEO of Mabion S.A..
127 people are employed at Mabion S.A..
Mabion S.A. is based in Kutno, Lodz Voivodeship.
The NAICS codes for Mabion S.A. are [32541, 325, 3254, 32].
The SIC codes for Mabion S.A. are [28, 283].